Intestinal Research

Review

Inflammatory bowel diseases

Colitis and Crohn’s Foundation (India) consensus statements on use of 5-aminosalicylic acid in inflammatory bowel disease: Ajit Sood, Vineet Ahuja, Vandana Midha, Saroj Kant Sinha, C. Ganesh Pai, Saurabh Kedia, Varun Mehta, Sawan Bopanna, Philip Abraham, Rupa Banerjee, Shobna Bhatia, Karmabir Chakravartty, Sunil Dadhich, Devendra Desai, Manisha Dwivedi, Bhabhadev Goswami, Kirandeep Kaur, Rajeev Khosla, Ajay Kumar, Ramit Mahajan, S. P. Misra, Kiran Peddi, Shivaram Prasad Singh, Arshdeep Singh; Intest Res 2020;18(4):355-378. Published online July 13, 2020; DOI: https://doi.org/10.5217/ir.2019.09176

Despite several recent advances in therapy in inflammatory bowel disease (IBD), 5-aminosalicylic acid (5-ASA) therapy has retained its place especially in ulcerative colitis. This consensus on 5-ASA is obtained through a modified Delphi process, and includes guiding statements and recommendations based on literature evidence (randomized trials, and observational studies), clinical practice, and expert opinion on use of 5-ASA in IBD by Indian gastroenterologists. The aim is to aid practitioners in selecting appropriate treatment strategies and facilitate optimal use of 5-ASA in patients with IBD.

Citations

Citations to this article as recorded by

Optimizing 5-aminosalicylate for moderate ulcerative colitis: expert recommendations from the Asia-Pacific, Middle East, and Africa Inflammatory Bowel Disease Coalition
Filiz Akyüz, Yoon Kyo An, Jakob Begun, Satimai Aniwan, Huu Hoang Bui, Webber Chan, Chang Hwan Choi, Nazeer Chopdat, Susan J Connor, Devendra Desai, Emma Flanagan, Taku Kobayashi, Allen Yu-Hung Lai, Rupert W Leong, Alex Hwong-Ruey Leow, Wai Keung Leung, Ju
Intestinal Research.2025; 23(1): 37. CrossRef
Effectiveness of Tofacitinib in Ulcerative Proctitis Compared to Left Sided Colitis and Pancolitis
Arshdeep Singh, Ramit Mahajan, Vandana Midha, Kirandeep Kaur, Dharmatma Singh, Ramandeep Kaur, Shreya Garg, Kirti Arora, Namita Bansal, Ajit Sood
Digestive Diseases and Sciences.2024; 69(4): 1389. CrossRef
The impact of 5-aminosalicylates on the efficacy of mesenchymal stem cell therapy in a murine model of ulcerative colitis
Huanhuan Chen, Huimin Wang, XiaoJing Xu, Ya'nan Hu, Jing Su, Dongdong Li, Zimu Li, Shixiang Feng, Jinming Liu, Huanxiang Zhang, Xiaoyan Wang
International Immunopharmacology.2024; 134: 112255. CrossRef
The impact of clinical experience on decision-making regarding the treatment and management of mild-to-moderate ulcerative colitis
Jae Hee Cheon, Kristine Paridaens, Sameer Al Awadhi, Jakob Begun, John R Fullarton, Edouard Louis, Fernando Magro, Juan Ricardo Marquez, Alexander R Moschen, Neeraj Narula, Grazyna Rydzewska, Axel U Dignass, Simon PL Travis
Intestinal Research.2023; 21(1): 161. CrossRef
Development of Novel pH-Sensitive Eudragit Coated Beads Containing Curcumin-Mesalamine Combination for Colon-Specific Drug Delivery
Eman J. Heikal, Rashad M. Kaoud, Shadeed Gad, Hatem I. Mokhtar, Abdullah Alattar, Reem Alshaman, Sawsan A. Zaitone, Yasser M. Moustafa, Taha M. Hammady
Gels.2023; 9(4): 264. CrossRef
Consenso colombiano de la enfermedad inflamatoria intestinal pediátrica
José Fernando Vera Chamorro, Claudia Sánchez Franco, Melquicedec Vargas Sandoval, Diana Victoria Mora Quintero, Juan Pablo Riveros López, Fernando Sarmiento Quintero, Catalina Ortiz-Piedrahita, Otto Gerardo Calderón-Guerrero, Hugo Laignelet, Claudia Lilia
Revista colombiana de Gastroenterología.2023; 38(Supl No. 1): 1. CrossRef
Clinical Features and Long-Term Outcomes of Paediatric-Onset Inflammatory Bowel Disease in a Population-Based Cohort in the Songpa-Kangdong District of Seoul, Korea
Sang Hyoung Park, Jong Pil Im, Hyunju Park, Seung Kyu Jeong, Ji Hyun Lee, Kyoung Hoon Rhee, Young-Ho Kim, Sung Noh Hong, Kyung Ho Kim, Seung In Seo, Jae Myung Cha, Sun Yong Park, Joo Sung Kim, Hyuk Yoon, Sung Hoon Kim, Jisun Jang, Jeong Hwan Kim, Seong O
Journal of Crohn's and Colitis.2022; 16(2): 207. CrossRef
Serum inter-alpha-trypsin inhibitor heavy chain 4 in patients with inflammatory bowel disease: correlation with disease risk, inflammation, activity, and its variation after treatment
Nuan Wen, Na Zhao, Huixian Xu, Ying Zhao, Jian Ma
Irish Journal of Medical Science (1971 -).2022; 191(5): 2105. CrossRef
5-Aminosalicylic Acid-induced Myocarditis in a Patient with Atypical Ulcerative Colitis
Hyo Yeop Song, Geom Seog Seo
The Korean Journal of Gastroenterology.2022; 79(1): 31. CrossRef
The Prognostic Value of Residual Nonrectal Inflammation in Ulcerative Colitis
Eun Ae Kang
Gut and Liver.2022; 16(3): 487. CrossRef
Updates on conventional therapies for inflammatory bowel diseases: 5-aminosalicylates, corticosteroids, immunomodulators, and anti-TNF-α
Jihye Park, Jae Hee Cheon
The Korean Journal of Internal Medicine.2022; 37(5): 895. CrossRef
Oral beclomethasone dipropionate as an add-on therapy and response prediction in Korean patients with ulcerative colitis
Kyuwon Kim, Hee Seung Hong, Kyunghwan Oh, Jae Yong Lee, Seung Wook Hong, Jin Hwa Park, Sung Wook Hwang, Dong-Hoon Yang, Jeong-Sik Byeon, Seung-Jae Myung, Suk-Kyun Yang, Byong Duk Ye, Sang Hyoung Park
The Korean Journal of Internal Medicine.2022; 37(6): 1140. CrossRef
Treatment of inflammatory bowel diseases: focusing on 5-aminosalicylates and immunomodulators
You Sun Kim
Journal of the Korean Medical Association.2021; 64(9): 596. CrossRef
Pharmacogenetics-based personalized treatment in patients with inflammatory bowel disease: A review
Ji Young Chang, Jae Hee Cheon
Precision and Future Medicine.2021; 5(4): 151. CrossRef

11,666 View
367 Download
14 Web of Science
14 Crossref

Original Articles

IBD

High risk of tuberculosis during infliximab therapy despite tuberculosis screening in inflammatory bowel disease patients in India: Ashish Agarwal, Saurabh Kedia, Saransh Jain, Vipin Gupta, Sawan Bopanna, Dawesh P Yadav, Sandeep Goyal, Venigalla Pratap Mouli, Rajan Dhingra, Govind Makharia, Vineet Ahuja; Intest Res 2018;16(4):588-598. Published online October 10, 2018; DOI: https://doi.org/10.5217/ir.2018.00023

Abstract PDF PubReader ePub

Background/Aims
The data on the risk of tuberculosis (TB) reactivation with infliximab (IFX) in patients with inflammatory bowel disease (IBD) from TB endemic countries, like India, is limited. The risk of TB reactivation on IFX and its predictors in patients with IBD was assessed.
Methods
This retrospective review included consecutive patients with IBD who received IFX, and were on follow-up from January 2005 to November 2017. The data was recorded on age/disease duration, indications for IFX, screening for latent tuberculosis (LTB) before IFX, response to IFX, incidence and duration when TB developed after IFX, and type of TB (pulmonary [PTB]/extra-pulmonary [EPTB]/disseminated).
Results
Of 69 patients (22 ulcerative colitis/47 Crohn’s disease; mean age, 35.6±14.5 years; 50.7% males; median follow-up duration after IFX, 19 months [interquartile range, 5.5–48.7 months]), primary non-response at 8 weeks and secondary loss of response at 26 and 52 weeks were seen in 14.5%, 6% and 15% patients respectively. Prior to IFX, all patients were screened for LTB, 8 (11.6%) developed active TB (disseminated, 62.5%; EPTB, 25%; PTB, 12.5%) after a median of 19 weeks (interquartile range, 14.0–84.5 weeks) of IFX. Of these 8 patients’ none had LTB, even when 7 of 8 were additionally screened with contrast-enhanced chest tomography. Though not statistically significant, more patients with Crohn’s disease than ulcerative colitis (14.9% vs. 4.5%, P=0.21), and those with past history of TB (25% vs. 9.8%, P=0.21), developed TB. Age, gender, disease duration, or extraintestinal manifestations could not predict TB reactivation.
Conclusions
There is an extremely high rate of TB with IFX in Indian patients with IBD. Current screening techniques are ineffective and it is difficult to predict TB after IFX.

Citations

Citations to this article as recorded by

Risk of tuberculosis with anti-TNF therapy in Indian patients with inflammatory bowel disease despite negative screening
Suprabhat Giri, Sukanya Bhrugumalla, Akash Shukla, Sagar Gangadhar, Srujan Reddy, Sumaswi Angadi, Leela Shinde, Aditya Kale
Arab Journal of Gastroenterology.2025; 26(1): 33. CrossRef
Assessment and management for latent tuberculosis before advanced therapies for immune-mediated inflammatory diseases: A comprehensive review
Daya Krishna Jha, Rinkalben Kakadiya, Ananya Sharma, Shankar Naidu, Dipankar De, Vishal Sharma
Autoimmunity Reviews.2025; 24(3): 103758. CrossRef
Biologics, Small Molecules and More in Inflammatory Bowel Disease: The Present and the Future
Manish Manrai, Atul Abhishek Jha, Saurabh Dawra, Aditya Vikram Pachisia
Future Pharmacology.2024; 4(1): 279. CrossRef
RATE OF INFECTION (TUBERCULOSIS) IN BRAZILIANS IBD PRIVATE PATIENTS: FOLLOW-UP 15 YEARS
Didia B CURY, Liana C B CURY, Ana C MICHELETTI, Rogério A OLIVEIRA, José J S GONÇALVES
Arquivos de Gastroenterologia.2024;[Epub] CrossRef
(Re-)introduction of TNF antagonists and JAK inhibitors in patients with previous tuberculosis: a systematic review
Thomas Theo Brehm, Maja Reimann, Niklas Köhler, Christoph Lange
Clinical Microbiology and Infection.2024; 30(8): 989. CrossRef
“Mitigating tuberculosis reactivation risk in IBD patients on anti-TNF therapy”
Peeyush Kumar, Saurabh Kedia, Vineet Ahuja
Arab Journal of Gastroenterology.2024; 25(4): 455. CrossRef
Regional risk of tuberculosis and viral hepatitis with tumor necrosis factor-alpha inhibitor treatment: A systematic review
Nina Jahnich, Peter D. Arkwright
Frontiers in Pharmacology.2023;[Epub] CrossRef
Bronchoesophageal fistula in a patient with Crohn’s disease receiving anti-tumor necrosis factor therapy
Kyunghwan Oh, Kee Don Choi, Hyeong Ryul Kim, Tae Sun Shim, Byong Duk Ye, Suk-Kyun Yang, Sang Hyoung Park
Clinical Endoscopy.2023; 56(2): 239. CrossRef
CT in the detection of latent tuberculosis: a systematic review
N. Moore, M. Maher, G. Murphy, M. O'Callaghan Maher, O.J. O'Connor, M.F. McEntee
Clinical Radiology.2023; 78(8): 568. CrossRef
Miliary Tuberculosis in a Patient With Ulcerative Colitis Treated With Tofacitinib
Shruti Verma, Arshdeep Singh, Chandan Kakkar, Ashish Tripathi, Vandana Midha, Ajit Sood
ACG Case Reports Journal.2023; 10(6): e01066. CrossRef
The Risk of Opportunistic Infections in Patients with Inflammatory Bowel Disease
Maede Ghanaeipour, Nima Behnaminia, Erfan Khadem, Amirhossein Nafari
The International Journal of Gastroenterology and Hepatology Diseases.2022;[Epub] CrossRef
Association of Tumor Necrosis Factor α Inhibitor Use with Diagnostic Features and Mortality of Tuberculosis in the United States, 2010–2017
Shereen S Katrak, Rongxia Li, Sue Reynolds, Suzanne M Marks, Jessica R Probst, Terence Chorba, Kevin Winthrop, Kenneth G Castro, Neela D Goswami
Open Forum Infectious Diseases.2022;[Epub] CrossRef
Stringent screening strategy significantly reduces reactivation rates of tuberculosis in patients with inflammatory bowel disease on anti‐TNF therapy in tuberculosis endemic region
Peeyush Kumar, Sudheer K. Vuyyuru, Bhaskar Kante, Pabitra Sahu, Sandeep Goyal, Deepak Madhu, Saransh Jain, Mukesh Kumar Ranjan, Sandeep Mundhra, Rithvik Golla, Mukesh Singh, Shubi Virmani, Anvita Gupta, Nidhi Yadav, Mani Kalaivani, Raju Sharma, Prasenjit
Alimentary Pharmacology & Therapeutics.2022; 55(11): 1431. CrossRef
Increased Risk of Infection With High Infliximab Trough Level
Suprabhat Giri, Harish Darak
Journal of Clinical Gastroenterology.2022; 56(4): 374. CrossRef
Editorial: choosing the optimal screening method for latent TB in patients with IBD commencing anti‐TNF‐therapy—authors' reply
Peeyush Kumar, Sudheer Kumar Vuyyuru, Saurabh Kedia, Vineet Ahuja
Alimentary Pharmacology & Therapeutics.2022; 55(10): 1348. CrossRef
Positioning of tofacitinib in treatment of ulcerative colitis: a global perspective
Shubhra Mishra, Anuraag Jena, Rinkalben Kakadiya, Vishal Sharma, Vineet Ahuja
Expert Review of Gastroenterology & Hepatology.2022; 16(8): 737. CrossRef
Tumor necrosis factor-alpha antibody labeled-polyethylene glycol-coated nanoparticles: A mesenchymal stem cells-based drug delivery system in the rat model of cisplatin-induced nephrotoxicity
Faten A. M. Abo-Aziza, Saleh M. Albarrak, Abdel-Kader A. Zaki, Shaymaa E. El-Shafey
Veterinary World.2022; : 2475. CrossRef
Efficacy and safety of biosimilar versus originator infliximab in patients with inflammatory bowel disease: A real-world cohort analysis
Peeyush Kumar, Sudheer K. Vuyyuru, Bhaskar Kante, Saurabh Kedia, Pabitra Sahu, Mukesh Kumar Ranjan, Sandeep Mundhra, Rithvik Golla, Mukesh Kumar, Shubi Virmani, Anvita Gupta, Nidhi Yadav, Govind Makharia, Vineet Ahuja
Indian Journal of Gastroenterology.2022; 41(5): 446. CrossRef
Epidemiology, burden of disease, and unmet needs in the treatment of ulcerative colitis in Asia
Shu-Chen Wei, Jose Sollano, Yee Tak Hui, Wei Yu, Paul V. Santos Estrella, Lyndon John Q. Llamado, Nana Koram
Expert Review of Gastroenterology & Hepatology.2021; 15(3): 275. CrossRef
Various Forms of Tuberculosis in Patients with Inflammatory Bowel Diseases Treated with Biological Agents
Adam Krusiński, Anna Grzywa-Celińska, Katarzyna Szewczyk, Luiza Grzycka-Kowalczyk, Justyna Emeryk-Maksymiuk, Janusz Milanowski, Andrew S. Day
International Journal of Inflammation.2021; 2021: 1. CrossRef
Long‐term outcomes of anti‐tumor necrosis factor therapy and surgery in nonperianal fistulizing Crohn's disease
Sudheer K Vuyyuru, Devendra Desai, Saurabh Kedia, Pavan Dhoble, Pabitra Sahu, Bhaskar Kante, Samagra Agarwal, Sawan Bopanna, Rajan Dhingra, Pratap Mouli Venigalla, Raju Sharma, Siddhartha Datta Gupta, Govind Makharia, Peush Sahni, Vineet Ahuja
JGH Open.2021; 5(4): 420. CrossRef
Efficacy and tolerability of exclusive enteral nutrition in adult patients with complicated Crohn’s disease
Sanchit Sharma, Arti Gupta, Saurabh Kedia, Samagra Agarwal, Namrata Singh, Sandeep Goyal, Saransh Jain, Vipin Gupta, Pabitra Sahu, Sudheer Kumar Vuyyuru, Bhaskar Kante, Raju Sharma, Rajesh Panwar, Peush Sahni, Govind Makharia, Vineet Ahuja
Intestinal Research.2021; 19(3): 291. CrossRef
Monitoring frequency of interferon gamma release assay for tuberculosis surveillance following infliximab therapy in patients with Crohn's disease
Qin Yu Yang, Yi Juan Liu, Ye Xu, Lin Zhang, Cheng Dang Wang
Journal of Digestive Diseases.2021; 22(8): 473. CrossRef
COVID-19-associated opportunistic infections: a snapshot on the current reports
Amir Abdoli, Shahab Falahi, Azra Kenarkoohi
Clinical and Experimental Medicine.2021; 22(3): 327. CrossRef
Efficacy and Safety of Fecal Transplantation Versus Targeted Therapies in Ulcerative Colitis: Network Meta-Analysis
Sudheer K Vuyyuru, Saurabh Kedia, Mani Kalaivani, Pabitra Sahu, Bhaskar Kante, Peeyush Kumar, Mukesh K Ranjan, Govind Makharia, Ashwin Ananthakrishnan, Vineet Ahuja
Future Microbiology.2021; 16(15): 1215. CrossRef
A case report of probable ocular tuberculosis following biologics
Sudha K. Ganesh, Divya Thatikonda
Indian Journal of Ophthalmology - Case Reports.2021; 1(4): 683. CrossRef
Risk and characteristics of tuberculosis after anti-tumor necrosis factor therapy for inflammatory bowel disease: a hospital-based cohort study from Korea
Jae Yong Lee, Kyunghwan Oh, Hee Seung Hong, Kyuwon Kim, Seung Wook Hong, Jin Hwa Park, Sung Wook Hwang, Dong-Hoon Yang, Byong Duk Ye, Jeong-Sik Byeon, Seung-Jae Myung, Suk-Kyun Yang, Ho-Su Lee, Kyung-Wook Jo, Sang Hyoung Park
BMC Gastroenterology.2021;[Epub] CrossRef
Tacrolimus as rescue therapy for steroid-dependent/steroid-refractory ulcerative colitis: Experience from tertiary referral center in India
Sukrit Sud, Sanjeev Sachdeva, Amarender Singh Puri
Indian Journal of Gastroenterology.2021; 40(6): 598. CrossRef
Vedolizumab in Inflammatory Bowel Disease: West versus East
Prasanta Debnath, Pravin M. Rathi
Inflammatory Intestinal Diseases.2021; 6(1): 1. CrossRef
Antitubercular Therapy Given to Differentiate Crohn’s Disease From Intestinal Tuberculosis Predisposes to Stricture Formation
Akshita Gupta, Venigalla Pratap Mouli, Srikant Mohta, Bhaskar Kante, Mani Kalaivani, Deepak Madhu, Pabitra Sahu, Sudheer Kumar, Raju Sharma, Peush Sahni, Prasenjit Das, Siddharth Datta Gupta, Govind Makharia, Saurabh Kedia, Vineet Ahuja
Journal of Crohn's and Colitis.2020; 14(11): 1611. CrossRef
Relapse rate following withdrawal of anti-TNF therapy in patients with inflammatory bowel disease: A real-life cohort from northern India
Pabitra Sahu, Sudheer K. Vuyyuru, Bhaskar Kante, Ashish Agarwal, Raju Sharma, Prasenjit Das, Rajesh Panwar, Saransh Jain, Sawan Bopanna, Govind Makharia, Saurabh Kedia, Vineet Ahuja
Indian Journal of Gastroenterology.2020; 39(4): 388. CrossRef
Nanocomposites-based targeted oral drug delivery systems with infliximab in a murine colitis model
Jung Min Kim, Da Hye Kim, Hyo Jeong Park, Hyun Woo Ma, I Seul Park, Mijeong Son, So Youn Ro, Seokmann Hong, Hyo Kyung Han, Soo Jeong Lim, Seung Won Kim, Jae Hee Cheon
Journal of Nanobiotechnology.2020;[Epub] CrossRef
Long-term outcomes in perianal fistulizing Crohn’s disease in a resource-limited setting: A cohort analysis
Sudheer K. Vuyyuru, Pabitra Sahu, Saurabh Kedia, Bhaskar Kante, Peeyush Kumar, Mukesh Kumar Ranjan, Raju Sharma, Govind Makharia, S. D. Gupta, Peush Sahni, Vineet Ahuja
Indian Journal of Gastroenterology.2020; 39(5): 435. CrossRef
Higher risk of tuberculosis in combination therapy for inflammatory bowel disease
Seong Ji Choi, Min Sun Kim, Eun Sun Kim, Juneyoung Lee, Jae Min Lee, Hyuk Soon Choi, Bora Keum, Yoon Tae Jeen, Hong Sik Lee, Hoon Jai Chun, Chang Duck Kim
Medicine.2020; 99(44): e22897. CrossRef
Challenges in the diagnosis and management of inflammatory bowel disease in resource-limited settings in Asia
Rupa Banerjee, Partha Pal, Joyce Wing Yan Mak, Siew C Ng
The Lancet Gastroenterology & Hepatology.2020; 5(12): 1076. CrossRef
Effectiveness and safety of adalimumab biosimilar in inflammatory bowel disease: A multicenter study
Nagesh Kamat, Saurabh Kedia, Uday C. Ghoshal, Abhimanyu Nehra, Govind Makharia, Ajit Sood, Vandana Midha, Varun Gupta, Gourdas Choudhuri, Vineet Ahuja
Indian Journal of Gastroenterology.2019; 38(1): 44. CrossRef
Multidrug-resistant Disseminated Tuberculosis Related to Infliximab in a Patient with Ulcerative Colitis and Negative Evaluation for Latent Tuberculosis
Yu Kyung Jun, Jaeyoung Chun, Eun Ae Kang, Hyun Jung Lee, Jong Pil Im, Joo Sung Kim
The Korean Journal of Gastroenterology.2019; 74(3): 168. CrossRef

8,900 View
204 Download
34 Web of Science
37 Crossref

IBD

Are Truelove and Witts criteria for diagnosing acute severe colitis relevant for the Indian population? A prospective study: Saransh Jain, Saurabh Kedia, Sawan Bopanna, Dawesh P Yadav, Sandeep Goyal, Peush Sahni, Sujoy Pal, Nihar Ranjan Dash, Govind Makharia, Simon P. L. Travis, Vineet Ahuja; Intest Res 2018;16(1):69-74. Published online January 18, 2018; DOI: https://doi.org/10.5217/ir.2018.16.1.69

Abstract PDF PubReader ePub

Background/Aims

Truelove and Witts criteria have been used to define acute severe colitis since the 1950s. However, hemoglobin (an additional criterion of the definition) levels in the general population in developing countries are lower than in the population of developed countries. We aimed to determine the relevance of Truelove and Witts criteria in the Indian population.

Methods

Consecutive patients with acute severe colitis satisfying the Truelove and Witts criteria, hospitalized at a single center between April 2015 and December 2016 were included. All patients received intravenous corticosteroids and 16 required colectomy. The hemoglobin levels at admission were subsequently excluded from the classification criteria, and the effect this had on the criteria for diagnosis was determined.

Results

Out of 61 patients of acute severe colitis diagnosed according to the original Truelove and Witts criteria, 12 patients (20%) had 1 additional criterion, 33 (54%) had 2 additional criteria and 16 (26%) had 3 or more additional criteria in addition to 6 or more blood stained stools on admission. On excluding hemoglobin as an additional criterion from the Truelove and Witts definition, all patients still met the criteria for acute severe colitis.

Conclusions

Truelove and Witts criteria can be used to define acute severe colitis in India, despite lower mean hemoglobin in the native population.

Citations

Citations to this article as recorded by

Early management of acute severe UC in the biologics era: development and international validation of a prognostic clinical index to predict steroid response
Alex Adams, Vipin Gupta, Waled Mohsen, Thomas P Chapman, Deloshaan Subhaharan, Pradeep Kakkadasam Ramaswamy, Sudheer Kumar, Saurabh Kedia, Colleen GC McGregor, Tim Ambrose, Bruce D George, Rebecca Palmer, Oliver Brain, Alissa Walsh, Vineet Ahuja, Simon P
Gut.2023; 72(3): 433. CrossRef
Inflammatory bowel disease
Mayank Jain, Jayanthi Venkataraman
Indian Journal of Medical Research.2021; 153(4): 421. CrossRef
High Serum Osmolality May Predict the Disease Severity in Patients with Acute Ulcerative Colitis
Abdussamed VURAL, Aslı VURAL, Selahattin VURAL, Selim TURFAN, Ahmet Cumhur DÜLGER
Online Türk Sağlık Bilimleri Dergisi.2020; 5(2): 324. CrossRef
Relationship Between Vitamin D Deficiency and Disease Activity in Patients with Inflammatory Bowel Disease in Ahvaz, Iran

Esmat Rasouli, Narges Sadeghi, Abazar Parsi, Seyed Jalal Hashemi, Morteza Nayebi, Aliakbar Shayesteh
Clinical and Experimental Gastroenterology.2020; Volume 13: 419. CrossRef
A current overview of corticosteroid use in active ulcerative colitis
Marco Salice, Fernando Rizzello, Carlo Calabrese, Lucia Calandrini, Paolo Gionchetti
Expert Review of Gastroenterology & Hepatology.2019; 13(6): 557. CrossRef
Optimal management of acute severe ulcerative colitis
Saransh Jain, Vineet Ahuja, Jimmy K Limdi
Postgraduate Medical Journal.2019; 95(1119): 32. CrossRef
A challenge in diagnosis and management of ulcerative colitis in elderly patient with atypical presentation: A reported case
Panutchaya Kongon, Vorapatu Tangsirapat, Vittawat Ohmpornuwat, Kannakrit Sumtong, Vichack Chakrapan Na Ayudhya, Kobkool Chakrapan Na Ayudhya, Paiboon Sookpotarom, Paisarn Vejchapipat
International Journal of Surgery Case Reports.2019; 61: 234. CrossRef

8,745 View
84 Download
6 Web of Science
7 Crossref

Familial aggregation of inflammatory bowel disease in patients with ulcerative colitis: Akshita Gupta, Sawan Bopanna, Saurabh Kedia, Dawesh Prakash Yadav, Sandeep Goyal, Saransh Jain, Govind Makharia, Vineet Ahuja; Intest Res 2017;15(3):388-394. Published online June 12, 2017; DOI: https://doi.org/10.5217/ir.2017.15.3.388

Abstract PDF PubReader ePub

Background/Aims

Familial occurrence of inflammatory bowel disease (IBD) is well documented. Reports from Western countries have shown a higher familial occurrence of ulcerative colitis (UC) in first- and second-degree relatives than that in the Asian UC population. No data are currently available from the Indian subcontinent in this regard. We present our data on the familial aggregation of UC.

Methods

Records of patients with UC followed at the Inflammatory Bowel Disease Clinic at the All India Institute of Medical Sciences, New Delhi from August 2004 to January 2016 were reviewed. Details regarding the prevalence of family history and characteristics of these patients were recorded. Affected family members were contacted and disease characteristics were noted for assessment of familial aggregation.

Results

Of the 2,058 UC patients included in the analysis, a positive family history of IBD was confirmed in 31 patients (1.5%), 24 (77.4%) of whom had only first-degree relatives affected. All the affected relatives had UC and none had Crohn's disease. Among first-degree relatives, siblings were found to have the highest prevalence of IBD (53.3%), followed by parents (26.7%).

Conclusions

The probability of occurrence of IBD in family members of affected North Indian UC patients is lower than that reported in Western populations.

Citations

Citations to this article as recorded by

The Impact of Smoking on Ulcerative Colitis and Interaction With Family History: A Population‐Based Cohort Study
Hyeong Sik Ahn, Heather Swan, Sayada Zartasha Kazmi, Young Shin Kim, Gahwi Hong, Seeun Choi, Taeuk Kang, Minjung Kim, Jaewoo Cha, Hoo Jae Hann, Hyun Jung Kim
Journal of Gastroenterology and Hepatology.2025; 40(2): 446. CrossRef
Inflammatory bowel disease in south Asia: a scoping review
Shabari Shenoy, Anuraag Jena, Carrie Levinson, Vishal Sharma, Parakkal Deepak, Tina Aswani-Omprakash, Shaji Sebastian, Jean-Frederic Colombel, Manasi Agrawal
The Lancet Gastroenterology & Hepatology.2025; 10(3): 259. CrossRef
Shared Pathophysiology of Inflammatory Bowel Disease and Psoriasis: Unraveling the Connection
Shadi Tabbarah, Hakam Sulaiman, Frank Ansah Owusu, Megha Rajeev Joshi, Nitheesha Reddy Marepalli, Nohelia Pino, Samra Saleem Azam, Aaliya Ali Ahmed, José Abraham Suárez Álvarez
Cureus.2024;[Epub] CrossRef
Childhood antibiotics as a risk factor for Crohn's disease: The ENIGMA International Cohort Study
Joyce W Y Mak, Sun Yang, Annalise Stanley, Xiaoqing Lin, Mark Morrison, Jessica Y L Ching, Junkun Niu, Amy L Wilson‐O'Brien, Rui Feng, Whitney Tang, Amy L Hamilton, Leo Or, Gina L Trakman, Winnie Y Y Lin, Joseph J Y Sung, Ming Hu Chen, Yinglei Mao, Michae
JGH Open.2022; 6(6): 369. CrossRef
Does the road to primary prevention of inflammatory bowel disease start from childhood?
Saurabh Kedia, Vineet Ahuja
JGH Open.2022; 6(6): 365. CrossRef
Cross Talk between Gut Microbiota and Intestinal Mucosal Immunity in the Development of Ulcerative Colitis
Junfeng Zou, Chen Liu, Shu Jiang, Dawei Qian, Jinao Duan, Anthony R. Richardson
Infection and Immunity.2021;[Epub] CrossRef
Factors Affecting Ulcerative Colitis Flare-Ups: Associations With Smoking Habits and Other Patient Characteristics
Nadim H Malibary, Mohammed A Ezzat, Ahmed M Mogharbel, Khalid A Kouzaba, Abdulaziz A Alkadi, Usama H Malki, Sultan M Gharib, Faisal M Altowairqi, Omar I Saadah, Mahmoud H Mosli
Cureus.2021;[Epub] CrossRef
Inflammatory bowel disease
Mayank Jain, Jayanthi Venkataraman
Indian Journal of Medical Research.2021; 153(4): 421. CrossRef
Familial aggregation of inflammatory bowel disease in India: prevalence, risks and impact on disease behavior
Rupa Banerjee, Partha Pal, Susan Hutfless, B Girish Ganesh, D Nageshwar Reddy
Intestinal Research.2019; 17(4): 486. CrossRef
Decreased Breg/Th17 Ratio Improved the Prognosis of Patients with Ulcerative Colitis
Xue Bing, Liang Linlang, Chen Keyan
Canadian Journal of Gastroenterology and Hepatology.2018; 2018: 1. CrossRef
Is the emergence of inflammatory bowel disease a prime example of “the third epidemiological transition”?
Saurabh Kedia, Vineet Ahuja
Indian Journal of Gastroenterology.2018; 37(3): 183. CrossRef

6,801 View
43 Download
12 Web of Science
11 Crossref

Evaluation of Xpert MTB/RIF assay performance in the diagnosis of abdominal tuberculosis: Suraj Kumar, Sawan Bopanna, Saurabh Kedia, Pratap Mouli, Rajan Dhingra, Rajesh Padhan, Mikashmi Kohli, Jigyasa Chaubey, Rohini Sharma, Prasenjit Das, S Dattagupta, Govind Makharia, SK Sharma, Vineet Ahuja; Intest Res 2017;15(2):187-194. Published online April 27, 2017; DOI: https://doi.org/10.5217/ir.2017.15.2.187

Abstract PDF PubReader ePub

Background/Aims

The use of genetic probes for the diagnosis of pulmonary tuberculosis (TB) has been well described. However, the role of these assays in the diagnosis of intestinal tuberculosis is unclear. We therefore assessed the diagnostic utility of the Xpert Mycobacterium tuberculosis/rifampicin (MTB/RIF) assay, and estimated the prevalence of multidrug-resistant (MDR) TB in the Indian population.

Methods

Of 99 patients recruited, 37 had intestinal TB; two control groups comprised 43 with Crohn's disease (CD) and 19 with irritable bowel syndrome. Colonoscopy was performed before starting any therapy; mucosal biopsies were subjected to histopathology, acid-fast bacilli staining, Lowenstein-Jensen culture, and nucleic acid amplification testing using the Xpert MTB/RIF assay. Patients were followed up for 6 months to confirm the diagnosis and response to therapy. A composite reference standard was used for diagnosis of TB and assessment of the diagnostic utility of the Xpert MTB/RIF assay.

Results

Of 37 intestinal TB patients, the Xpert MTB/RIF assay was positive in three of 37 (8.1%), but none had MDR-TB. The sensitivity, specificity, positive predictive value, and negative predictive value of the Xpert MTB/RIF assay was 8.1%, 100%, 100%, and, 64.2%, respectively.

Conclusions

The Xpert MTB/RIF assay has low sensitivity but high specificity for intestinal TB, and may be helpful in endemic tuberculosis areas, when clinicians are faced with difficulty differentiating TB and CD. Based on the Xpert MTB/RIF assay, the prevalence of intestinal MDR-TB is low in the Indian population.

Citations

Citations to this article as recorded by

Mistakes to avoid in the management of abdominal tuberculosis
Abhirup Chatterjee, Daya Krishna Jha, Aravind Sekar, Vishal Sharma
Expert Review of Anti-infective Therapy.2025; : 1. CrossRef
Non-celiac Enteropathies
Kaitlyn Mi, Scarlett Cao, Dawn Adams
Current Gastroenterology Reports.2025;[Epub] CrossRef
Perfusion Computed Tomography May Help in Discriminating Gastrointestinal Tuberculosis and Crohn’s Disease
Raghav Seth, Pankaj Gupta, Uma Debi, Kaushal Kishore Prasad, Harjeet Singh, Vishal Sharma
Diagnostics.2023; 13(7): 1255. CrossRef
Clinical characteristics and diagnosis of intestinal tuberculosis in clinical practice at Thailand’s largest national tertiary referral center: An 11-year retrospective review
Asawin Sudcharoen, Gahwin Ruchikajorndech, Sitthipong Srisajjakul, Ananya Pongpaibul, Popchai Ngamskulrungroj, Orawan Tulyaprawat, Julajak Limsrivilai, Mao-Shui Wang
PLOS ONE.2023; 18(4): e0282392. CrossRef
Analytical performances of the Xpert MTB/RIF assay using stool specimens to improve the diagnosis of pulmonary tuberculosis in Burkina Faso, a tuberculosis endemic country
Odilon D. Kaboré, Anselme Millogo, Bintou Sanogo, Emile Birba, Armel Poda, Boubacar Nacro, Olivier Marcy, Sylvain Godreuil, Abdoul-Salam Ouédraogo, Mao-Shui Wang
PLOS ONE.2023; 18(7): e0288671. CrossRef
Meta-analysis of diagnostic accuracy of nucleic acid amplification tests for abdominal tuberculosis
Yanqin Shen, Likui Fang, Bo Ye, Guocan Yu, Kamal Kishore Chopra
PLOS ONE.2023; 18(11): e0289336. CrossRef
Chapitre 7: La tuberculose extrapulmonaire
Leila Barss, William J. A. Connors, Dina Fisher
Canadian Journal of Respiratory, Critical Care, and Sleep Medicine.2023; 7(6): 365. CrossRef
Recent updates in diagnosis of abdominal tuberculosis with emphasis on nucleic acid amplification tests
Preeti Mor, Bhawna Dahiya, Sanjeev Parshad, Pooja Gulati, Promod K. Mehta
Expert Review of Gastroenterology & Hepatology.2022; 16(1): 33. CrossRef
Chapter 7: Extra-pulmonary tuberculosis
Leila Barss, William J. A. Connors, Dina Fisher
Canadian Journal of Respiratory, Critical Care, and Sleep Medicine.2022; 6(sup1): 87. CrossRef
Abdominal Tuberculosis Mimicking Ovarian Cancer: A Case Report and Review of the Literature
Ikhwan Rinaldi, Abdul Muthalib, Djaja Gosal, Teguh Wijayadi, Barlian Sutedja, Tjondro Setiawan, Andika Gunawan, Nelly Susanto, Lingga Magdalena, Diah Rini Handjari, Fetisari Kurniawan, Aisyah Rifani, Kevin Winston
International Medical Case Reports Journal.2022; Volume 15: 169. CrossRef
Intestinal Tuberculosis Presenting with Gastrointestinal Bleeding in Patient on Warfarin Therapy
Werimo Pascal Kuka, Joe Rakiro, Joseph Gatheru, Felix Riunga, Allan Rajula, Daniel C. Damin
Case Reports in Gastrointestinal Medicine.2022; 2022: 1. CrossRef
Evaluating diagnostic performance of Truenat MTB Plus for gastrointestinal tuberculosis
Kusum Sharma, Megha Sharma, Vishal Sharma, Megha Sharma, Jayanta Samanta, Aman Sharma, Rakesh Kochhar, Saroj Kant Sinha
Journal of Gastroenterology and Hepatology.2022; 37(8): 1571. CrossRef
Totally laparoscopic treatment of intestinal tuberculosis complicated with bowel perforation: The first case report in worldwide literature with a brief review
Giuseppe Di Buono, Roberta Vella, Giuseppe Amato, Giorgio Romano, Vito Rodolico, Marta Saverino, Giovanni De Lisi, Giorgio Romano, Salvatore Buscemi, Antonino Agrusa
Frontiers in Surgery.2022;[Epub] CrossRef
Acid fast bacillus smear, mycobacterial culture and Xpert MTB/RIF assay for the diagnosis of tuberculous peritonitis in patients with and without end stage renal failure
Richa Misra, Mitra Kar, Samir Mohindra, Amit Gupta
Access Microbiology .2022;[Epub] CrossRef
Diagnostic accuracy of the Xpert MTB/RIF assay for abdominal tuberculosis: a systematic review and meta-analysis
Vishal Sharma, Hariom Soni, Praveen Kumar-M, Saurabh Dawra, Shubhra Mishra, Harshal S Mandavdhare, Harjeet Singh, Usha Dutta
Expert Review of Anti-infective Therapy.2021; 19(2): 253. CrossRef
Xpert MTB/RIF Ultra and Xpert MTB/RIF assays for extrapulmonary tuberculosis and rifampicin resistance in adults
Mikashmi Kohli, Ian Schiller, Nandini Dendukuri, Mandy Yao, Keertan Dheda, Claudia M Denkinger, Samuel G Schumacher, Karen R Steingart
Cochrane Database of Systematic Reviews.2021;[Epub] CrossRef
Intestinal tuberculosis or Crohn's disease: Illusion or delusion or allusion
Saurabh Kedia, Vineet Ahuja
JGH Open.2021; 5(2): 177. CrossRef
Application value of tissue tuberculosis antigen combined with Xpert MTB/RIF detection in differential diagnoses of intestinal tuberculosis and Crohn’s disease
Baoying Fei, Lin Zhou, Yu Zhang, Linhe Luo, Yuanyuan Chen
BMC Infectious Diseases.2021;[Epub] CrossRef
Gastrointestinal tuberculosis
Adnan B. Al-Zanbagi, M. K. Shariff
Saudi Journal of Gastroenterology.2021; 27(5): 261. CrossRef
A combination of circulating microRNA-375-3p and chemokines CCL11, CXCL12, and G-CSF differentiate Crohn’s disease and intestinal tuberculosis
Susree Roy, Suchandrima Ghosh, Mallica Banerjee, Sayantan Laha, Dipanjan Bhattacharjee, Rajib Sarkar, Sujay Ray, Arko Banerjee, Ranajoy Ghosh, Aniket Halder, Alakendu Ghosh, Raghunath Chatterjee, Simanti Datta, Gopal Krishna Dhali, Soma Banerjee
Scientific Reports.2021;[Epub] CrossRef
An Outcome-Based Composite Approach for the Diagnosis of Intestinal Tuberculosis: A Pilot Study from a Tertiary Care Centre in South India
Roopa Rachel Paulose, V Anil Kumar, Aparna Sharma, Aditi Damle, Divya Saikumar, Abish Sudhakar, Anoop K Koshy, Rama P Venu
Journal of the Royal College of Physicians of Edinburgh.2021; 51(4): 344. CrossRef
Abdominal Tuberculosis in Children: Challenges, Uncertainty, and Confusion
Giulia Sartoris, James A Seddon, Helena Rabie, Etienne D Nel, H Simon Schaaf
Journal of the Pediatric Infectious Diseases Society.2020; 9(2): 218. CrossRef
How can gastro-intestinal tuberculosis diagnosis be improved? A prospective cohort study
Christopher Lowbridge, Soraya A. M. Fadhil, Gayathri D. Krishnan, Emma Schimann, Raman Muthu Karuppan, Nagaraj Sriram, Giri Shan Rajahram, Jayaram Menon, Aatish Patel, Timothy William, Dawn Carmel Paul, Anna P. Ralph
BMC Infectious Diseases.2020;[Epub] CrossRef
Abdominal Tuberculosis Mimicking Ovarian Cancer: A Diagnostic Dilemma
Anitha Thomas, Ajit Sebastian, Rachel George, Dhanya Susan Thomas, Grace Rebekah, Priscila Rupali, Joy Sarojini Michael, Abraham Peedicayil
The Journal of Obstetrics and Gynecology of India.2020; 70(4): 304. CrossRef
Apoptosis in peripheral blood lymphocytes in intestinal tuberculosis and Crohn’s disease: Implications to diagnostic differentiation
Suprabha Suresh Nayak, Mamatha Vishwanatha Shetty, Cannanore Ganesh Pai, Kanive Parashiva Guruprasad, Kapaettu Satyamoorthy
Indian Journal of Gastroenterology.2020; 39(4): 338. CrossRef
Tuberculose abdominale
I. Diallo, T. Omar Soko, A. Rajack Ndiaye, F. Klotz
EMC - Radiologie et imagerie médicale - Abdominale - Digestive.2020; 38(1): 1. CrossRef
Tuberculose abdominale
I. Diallo, T. Omar Soko, A. Rajack Ndiaye, F. Klotz
EMC - Gastro-entérologie.2020; 37(1): 1. CrossRef
Multiplex Polymerase Chain Reaction for diagnosis of gastrointestinal tuberculosis
Sarthak Malik, Kusum Sharma, Kim Vaiphei, Narendra Dhaka, Neha Berry, Pankaj Gupta, Megha Sharma, Bipadabhanjan Mallick, Rakesh Kochhar, Saroj K Sinha
JGH Open.2019; 3(1): 32. CrossRef
Differentiating Crohn’s disease from intestinal tuberculosis
Saurabh Kedia, Prasenjit Das, Kumble Seetharama Madhusudhan, Siddhartha Dattagupta, Raju Sharma, Peush Sahni, Govind Makharia, Vineet Ahuja
World Journal of Gastroenterology.2019; 25(4): 418. CrossRef
Utility of tissue Xpert-Mtb/Rif for the diagnosis of intestinal tuberculosis in patients with ileocolonic ulcers
Balaji L Bellam, Harshal S Mandavdhare, Kusum Sharma, Siddharth Shukla, Hariom Soni, Praveen Kumar-M, Harjeet Singh, Kaushal K Prasad, Usha Dutta, Vishal Sharma
Therapeutic Advances in Infectious Disease.2019;[Epub] CrossRef
GeneXpert in stool: Diagnostic yield in Intestinal Tuberculosis
Abu Talib, Shaheen Bhatty, Khalid Mehmood, Huda Naim, Iftikhar Haider, Hari Lal, Gohar Ali, Muhammad Nashit
Journal of Clinical Tuberculosis and Other Mycobacterial Diseases.2019; 17: 100131. CrossRef
GENEXPERT FOR ABDOMINAL TUBERCULOSIS
Alka SHARMA
Arquivos de Gastroenterologia.2019; 56(4): 454. CrossRef
A diagnostic approach for differentiating abdominal tuberculosis from ovarian malignancy: a case series and literature review
Moh Nailul Fahmi, Annisaa Pelita Harti
BMC Proceedings.2019;[Epub] CrossRef
Xpert®MTB/RIF assay for extrapulmonary tuberculosis and rifampicin resistance
Mikashmi Kohli, Ian Schiller, Nandini Dendukuri, Keertan Dheda, Claudia M Denkinger, Samuel G Schumacher, Karen R Steingart
Cochrane Database of Systematic Reviews.2018;[Epub] CrossRef
Surgery for Abdominal Tuberculosis in the Present Era: Experience from a Tertiary-Care Center
Harjeet Singh, Gautham Krishnamurthy, Jayapal Rajendran, Vishal Sharma, Harshal Mandavdhare, Hemanth Kumar, Thakur Deen Yadav, Rakesh Kumar Vasishta, Rajinder Singh
Surgical Infections.2018; 19(6): 640. CrossRef
Making a Positive Diagnosis of Intestinal Tuberculosis with the Aid of New Biologic and Histologic Features: How Far Have We Reached?
Vatsal Mehta, Devendra Desai, Philip Abraham, Camilla Rodrigues
Inflammatory Intestinal Diseases.2018; 3(4): 155. CrossRef
Editor’s Pick: Recent Advances in the Diagnosis and Management of Abdominal Tuberculosis
Harshal S. Mandavdhare, Harjeet Singh, Vishal Sharma
EMJ Gastroenterology.2017; : 52. CrossRef

7,440 View
100 Download
31 Web of Science
37 Crossref

Systematic Review

Accuracy of computed tomographic features in differentiating intestinal tuberculosis from Crohn's disease: a systematic review with meta-analysis: Saurabh Kedia, Raju Sharma, Vishnubhatla Sreenivas, Kumble Seetharama Madhusudhan, Vishal Sharma, Sawan Bopanna, Venigalla Pratap Mouli, Rajan Dhingra, Dawesh Prakash Yadav, Govind Makharia, Vineet Ahuja; Intest Res 2017;15(2):149-159. Published online April 27, 2017; DOI: https://doi.org/10.5217/ir.2017.15.2.149

Abstract PDF PubReader ePub

Abdominal computed tomography (CT) can noninvasively image the entire gastrointestinal tract and assess extraintestinal features that are important in differentiating Crohn's disease (CD) and intestinal tuberculosis (ITB). The present meta-analysis pooled the results of all studies on the role of CT abdomen in differentiating between CD and ITB. We searched PubMed and Embase for all publications in English that analyzed the features differentiating between CD and ITB on abdominal CT. The features included comb sign, necrotic lymph nodes, asymmetric bowel wall thickening, skip lesions, fibrofatty proliferation, mural stratification, ileocaecal area, long segment, and left colonic involvements. Sensitivity, specificity, positive and negative likelihood ratios, and diagnostic odds ratio (DOR) were calculated for all the features. Symmetric receiver operating characteristic curve was plotted for features present in >3 studies. Heterogeneity and publication bias was assessed and sensitivity analysis was performed by excluding studies that compared features on conventional abdominal CT instead of CT enterography (CTE). We included 6 studies (4 CTE, 1 conventional abdominal CT, and 1 CTE+conventional abdominal CT) involving 417 and 195 patients with CD and ITB, respectively. Necrotic lymph nodes had the highest diagnostic accuracy (sensitivity, 23%; specificity, 100%; DOR, 30.2) for ITB diagnosis, and comb sign (sensitivity, 82%; specificity, 81%; DOR, 21.5) followed by skip lesions (sensitivity, 86%; specificity, 74%; DOR, 16.5) had the highest diagnostic accuracy for CD diagnosis. On sensitivity analysis, the diagnostic accuracy of other features excluding asymmetric bowel wall thickening remained similar. Necrotic lymph nodes and comb sign on abdominal CT had the best diagnostic accuracy in differentiating CD and ITB.

Citations

Citations to this article as recorded by

Differentiation of Crohn's disease, ulcerative colitis, and intestinal tuberculosis by dual-layer spectral detector CT enterography
M. Huang, L. Tu, J. Li, X. Yue, L. Wu, M. Yang, Y. Chen, P. Han, X. Li, L. Zhu
Clinical Radiology.2024; 79(3): e482. CrossRef
Deep Learning Radiomics Analysis of CT Imaging for Differentiating Between Crohn’s Disease and Intestinal Tuberculosis
Ming Cheng, Hanyue Zhang, Wenpeng Huang, Fei Li, Jianbo Gao
Journal of Imaging Informatics in Medicine.2024; 37(4): 1516. CrossRef
New diagnostic strategies to distinguish Crohn's disease and gastrointestinal tuberculosis
Himanshu Narang, Saurabh Kedia, Vineet Ahuja
Current Opinion in Infectious Diseases.2024; 37(5): 392. CrossRef
Management and monitoring of pediatric inflammatory bowel disease in the Asia‐Pacific region: A position paper by the Asian Pan‐Pacific Society for Pediatric Gastroenterology, Hepatology, and Nutrition (APPSPGHAN) PIBD Working Group: Surgical management,
Way Seah Lee, Katsuhiro Arai, George Alex, Suporn Treepongkaruna, Kyung Mo Kim, Chee Liang Choong, Karen Calixto Mercado, Andy Darma, Anshu Srivastava, Marion M. Aw
Journal of Gastroenterology and Hepatology.2023; 38(4): 510. CrossRef
Granulomatous bowel disease: Crohn’s disease and tuberculosis. Difficulties in differential diagnosis (case report and review)
A. V. Vardanyan, E. S. Merkulova, V. A. Belinskaya, K. S. Frolova, O. A. Mainovskaya
Koloproktologia.2023; 22(1): 117. CrossRef
Evidence-based approach to diagnosis and management of abdominal tuberculosis
Daya Krishna Jha, Mythili Menon Pathiyil, Vishal Sharma
Indian Journal of Gastroenterology.2023; 42(1): 17. CrossRef
Differentiating gastrointestinal tuberculosis and Crohn's disease- a comprehensive review
Arup Choudhury, Jasdeep Dhillon, Aravind Sekar, Pankaj Gupta, Harjeet Singh, Vishal Sharma
BMC Gastroenterology.2023;[Epub] CrossRef
Recent updates in diagnosis of abdominal tuberculosis with emphasis on nucleic acid amplification tests
Preeti Mor, Bhawna Dahiya, Sanjeev Parshad, Pooja Gulati, Promod K. Mehta
Expert Review of Gastroenterology & Hepatology.2022; 16(1): 33. CrossRef
Addition of computed tomography chest increases the diagnosis rate in patients with suspected intestinal tuberculosis
Saurabh Kedia, Raju Sharma, Sudheer Kumar Vuyyuru, Deepak Madhu, Pabitra Sahu, Bhaskar Kante, Prasenjit Das, Ankur Goyal, Karan Madan, Govind Makharia, Vineet Ahuja
Intestinal Research.2022; 20(2): 184. CrossRef
Systematic reporting of computed tomography enterography/enteroclysis as an aid to reduce diagnostic dilemma when differentiating between intestinal tuberculosis and Crohn's disease: A prospective study at a tertiary care hospital
Amrin Israrahmed, Rajanikant R Yadav, Geeta Yadav, Alpana, Rajesh V Helavar, Praveer Rai, Manoj Kumar Jain, Archna Gupta
JGH Open.2021; 5(2): 180. CrossRef
Intestinal Tuberculosis: A Diagnostic Challenge
Hansang Park, Tikal Kansara, Ana M Victoria, Noella Boma, Jungrak Hong
Cureus.2021;[Epub] CrossRef
Intestinal tuberculosis or Crohn's disease: Illusion or delusion or allusion
Saurabh Kedia, Vineet Ahuja
JGH Open.2021; 5(2): 177. CrossRef
Deep‐learning system for real‐time differentiation between Crohn's disease, intestinal Behçet's disease, and intestinal tuberculosis
Jung Min Kim, Jun Gu Kang, Sungwon Kim, Jae Hee Cheon
Journal of Gastroenterology and Hepatology.2021; 36(8): 2141. CrossRef
Prospective validation of CD4+CD25+FOXP3+ T-regulatory cells as an immunological marker to differentiate intestinal tuberculosis from Crohn’s disease
Ritika Rampal, Saurabh Kedia, Mohamad Nahidul Wari, Deepak Madhu, Amit Kumar Singh, Veena Tiwari, V. Pratap Mouli, Srikant Mohta, Govind Makharia, Vineet Ahuja
Intestinal Research.2021; 19(2): 232. CrossRef
Correlation-driven framework based on graph convolutional network for clinical disease classification
Kai Cao, Ying Xiao, Muzhou Hou
Journal of Statistical Computation and Simulation.2021; 91(15): 3108. CrossRef
Difficulties in the differential diagnosis of intestinal tuberculosis and Crohn‘s disease
M. N. Reshetnikov, D. V. Plotkin, Yu. R. Zyuzya, A. A. Volkov, O. N. Zuban, E. M. Bogorodskaya
Acta Biomedica Scientifica.2021; 6(5): 196. CrossRef
Diagnostic performance of CT for differentiating peritoneal tuberculosis from peritoneal carcinomatosis: a systematic review and meta-analysis
J. Chen, S. Liu, Y. Tang, X. Zhang, M. Cao, Z. Xiao, M. Ren, T. Chen
Clinical Radiology.2020; 75(5): 396.e7. CrossRef
Disseminated tuberculosis presenting as massive lower gastrointestinal bleeding
Nehal Aggarwal, SubodhKumar Mahto, Akanskha Singh, Kritika Gupta, Ankita Aneja, Anu Singh, Atul Goel
Journal of Family Medicine and Primary Care.2020; 9(2): 1226. CrossRef
Differentiating Crohn’s disease from intestinal tuberculosis
Saurabh Kedia, Prasenjit Das, Kumble Seetharama Madhusudhan, Siddhartha Dattagupta, Raju Sharma, Peush Sahni, Govind Makharia, Vineet Ahuja
World Journal of Gastroenterology.2019; 25(4): 418. CrossRef
The potential role of CT enterography and gastrointestinal ultrasound in the evaluation of anti-tubercular therapy response of intestinal tuberculosis: a retrospective study
Li Ma, Qingli Zhu, Yue Li, Wenbo Li, Xuan Wang, Wei Liu, Jianchu Li, Yuxin Jiang
BMC Gastroenterology.2019;[Epub] CrossRef
Indian guidelines on imaging of the small intestine in Crohn’s disease: A joint Indian Society of Gastroenterology and Indian Radiology and Imaging Association consensus statement
Saurabh Kedia, Raju Sharma, Govind Makharia, Vineet Ahuja, Devendra Desai, Devasenathipathy Kandasamy, Anu Eapen, Karthik Ganesan, Uday C Ghosha, Naveen Kalra, R Karthikeyan, Kumble Seetharama Madhusudhan, Mathew Philip, Amarender Puri, Sunil Puri, Saroj
Indian Journal of Radiology and Imaging.2019; 29(02): 111. CrossRef
Imaging in discriminating intestinal tuberculosis and Crohn’s disease: past, present and the future
Pradeep Goyal, Jimil Shah, Sonali Gupta, Pankaj Gupta, Vishal Sharma
Expert Review of Gastroenterology & Hepatology.2019; 13(10): 995. CrossRef
Combination of increased visceral fat and long segment involvement: Development and validation of an updated imaging marker for differentiating Crohn's disease from intestinal tuberculosis
Saurabh Kedia, Kumble S Madhusudhan, Raju Sharma, Sawan Bopanna, Dawesh P Yadav, Sandeep Goyal, Saransh Jain, Prasenjit Das, Siddhartha Dattagupta, Govind Makharia, Vineet Ahuja
Journal of Gastroenterology and Hepatology.2018; 33(6): 1234. CrossRef
Computed Tomography Enterography: Quantitative Evaluation on Crohn’s Disease Activity
Jingyun Cheng, Hui Xie, Hao Yang, Ke Wang, Guobin Xu, Guangyao Wu
Gastroenterology Research and Practice.2018; 2018: 1. CrossRef
Gastrointestinal Tuberculosis Presenting as Malnutrition and Distal Colonic Bowel Obstruction
Raja Chandra Chakinala, Zahava C. Farkas, Benjamin Barbash, Khwaja F. Haq, Shantanu Solanki, Muhammad Ali Khan, Edward Esses, Taliya Farooq, Brad Dworkin
Case Reports in Gastrointestinal Medicine.2018; 2018: 1. CrossRef
Diagnostic point-of-care ultrasound (POCUS) for gastrointestinal pathology: state of the art from basics to advanced
Fikri M Abu-Zidan, Arif Alper Cevik
World Journal of Emergency Surgery.2018;[Epub] CrossRef
Enfermedad de Crohn vs tuberculosis intestinal: un diagnóstico diferencial desafiante. Revisión de tema
Gabriel Alonso Mosquera-Klinger, Andrea Ucroz Benavides
Revista Colombiana de Gastroenterología.2018; 33(4): 423. CrossRef
Imaging of the small intestine in Crohn’s disease: Joint position statement of the Indian Society of Gastroenterology and Indian Radiological and Imaging Association
Saurabh Kedia, Raju Sharma, Govind K. Makharia, Vineet Ahuja, Devendra Desai, Devasenathipathy Kandasamy, Anu Eapen, Karthik Ganesan, Uday C. Ghoshal, Naveen Kalra, D. Karthikeyan, Kumble Seetharama Madhusudhan, Mathew Philip, Amarender Singh Puri, Sunil
Indian Journal of Gastroenterology.2017; 36(6): 487. CrossRef
Editor’s Pick: Recent Advances in the Diagnosis and Management of Abdominal Tuberculosis
Harshal S. Mandavdhare, Harjeet Singh, Vishal Sharma
EMJ Gastroenterology.2017; : 52. CrossRef

8,978 View
149 Download
28 Web of Science
29 Crossref

Original Articles

Prevalence of hepatitis B, hepatitis C and human immunodeficiency viral infections in patients with inflammatory bowel disease in north India: Parnita Harsh, Vipin Gupta, Saurabh Kedia, Sawan Bopanna, Sucharita Pilli, Surendernath, Govind Kumar Makharia, Vineet Ahuja; Intest Res 2017;15(1):97-102. Published online January 31, 2017; DOI: https://doi.org/10.5217/ir.2017.15.1.97

Abstract PDF PubReader ePub

Background/Aims

Patients with inflammatory bowel disease (IBD) often require immunosuppressive therapy and blood transfusions and therefore are at a high risk of contracting infections due to hepatitis B (HBV) and hepatitis C (HCV) and human immunodeficiency virus (HIV). In the present study, we assessed the prevalence of these infections in patients with IBD.

Methods

This retrospective study included 908 consecutive patients with IBD (ulcerative colitis [UC], n=581; Crohn's disease [CD], n=327) who were receiving care at a tertiary care center. Ninety-five patients with intestinal tuberculosis (ITB) were recruited as disease controls. Prospectively maintained patient databases were reviewed for the prevalence of HBV surface antigen, anti-HCV antibodies, and HIV (enzyme-linked immunosorbent assay method). HCV RNA was examined in patients who tested positive for anti-HCV antibodies. Prevalence data of the study were compared with that of the general Indian population (HBV, 3.7%; HCV, 1%; HIV, 0.3%).

Results

The prevalence of HBV, HCV, and HIV was 2.4%, 1.4%, and 0.1%, respectively, in the 908 patients with IBD. Among the 581 patients with UC, 2.2% (12/541) had HBV, 1.7% (9/517) had HCV, and 0.2% (1/499) had HIV. Among the 327 patients with CD, 2.8% (8/288) had HBV, 0.7% (2/273) had HCV, and 0% (0/277) had HIV. One patient with CD had HBV and HCV coinfection. The prevalence of HBV, HCV, and HIV in patients with ITB was 5.9% (4/67), 1.8% (1/57), and 1.2% (1/84), respectively.

Conclusions

The prevalence of HBV, HCV, and HIV in north Indian patients with IBD is similar to the prevalence of these viruses in the general community. Nonetheless, the high risk of flare after immunosuppressive therapy mandates routine screening of patients with IBD for viral markers.

Citations

Citations to this article as recorded by

Brucellosis in a patient with Crohn's disease treated with infliximab: A case report
Mansour Altuwaijri, Nasser Alkhraiji, Mosaab Almasry, Saad Alkhowaiter, Nuha Al Amaar, Ammar Alotaibi
Arab Journal of Gastroenterology.2025; 26(1): 38. CrossRef
Managing IBD Patients with Concomitant HIV Infection - a Systematic Review
Hugo Sousa, Joana Barroso, Raquel Tavares, Joana Torres
Current Gastroenterology Reports.2024; 26(1): 1. CrossRef
Prevalence of hepatitis B virus and hepatitis C virus infection in patients with inflammatory bowel disease: a systematic review and meta-analysis
Suprabhat Giri, Dhiraj Agrawal, Shivaraj Afzalpurkar, Sunil Kasturi, Amrit Gopan, Sridhar Sundaram, Aditya Kale
Intestinal Research.2023; 21(3): 392. CrossRef
Expert consensus on vaccination in patients with inflammatory bowel disease in Japan
Takashi Ishige, Toshiaki Shimizu, Kenji Watanabe, Katsuhiro Arai, Koichi Kamei, Takahiro Kudo, Reiko Kunisaki, Daisuke Tokuhara, Makoto Naganuma, Tatsuki Mizuochi, Atsuko Murashima, Yuta Inoki, Naomi Iwata, Itaru Iwama, Sachi Koinuma, Hirotaka Shimizu, Ke
Journal of Gastroenterology.2023; 58(2): 135. CrossRef
Prevalence of viral hepatitis infection in India: A systematic review and meta-analysis
Dhasarathi Kumar, Roshni M. Peter, Alex Joseph, Kalpana Kosalram, Harpreet Kaur
Journal of Education and Health Promotion.2023;[Epub] CrossRef
Frequency of hepatitis C virus infection in patients with pediatric inflammatory bowel disease: a cross-sectional study
Sara Tarek, Ayman E. Eskander, Safa Meshaal, Eman Badr, Asmaa Abd El-Hakeem
Egyptian Pediatric Association Gazette.2023;[Epub] CrossRef
Pancreatic Disorders in Patients with Inflammatory Bowel Disease
Marilia L. Montenegro, Juan E. Corral, Frank J. Lukens, Baoan Ji, Paul T. Kröner, Francis A. Farraye, Yan Bi
Digestive Diseases and Sciences.2022; 67(2): 423. CrossRef
Vaccination strategies for Korean patients with inflammatory bowel disease
Yoo Jin Lee, Eun Soo Kim
The Korean Journal of Internal Medicine.2022; 37(5): 920. CrossRef
Viral Hepatitis in Patients with Inflammatory Bowel Disease
Seung Hwan Shin, Sang Hyoung Park
The Korean Journal of Gastroenterology.2022; 80(2): 51. CrossRef
Involvement of HHV-4 (Epstein–Barr Virus) and HHV-5 (Cytomegalovirus) in Inflammatory Bowel Disease and Colorectal Cancer: A Meta-Analysis
Luigi Marongiu, Sascha Venturelli, Heike Allgayer
Cancers.2022; 14(20): 5085. CrossRef
Prevalence of serological markers of hepatitis B in inflammatory bowel disease – Experience from a tertiary care centre in South India
Amol Prabhakar Patil, Ebby George Simon, Amit Kumar Dutta, Anjilivelil Joseph Joseph, Reuben Thomas Kurien, Sudipta Dhar Chowdhury
Tropical Doctor.2021; 51(3): 326. CrossRef
Comorbidity before and after a diagnosis of inflammatory bowel disease
Charles N. Bernstein, Zoann Nugent, Seth Shaffer, Harminder Singh, Ruth Ann Marrie
Alimentary Pharmacology & Therapeutics.2021; 54(5): 637. CrossRef
ECCO Guidelines on the Prevention, Diagnosis, and Management of Infections in Inflammatory Bowel Disease
T Kucharzik, P Ellul, T Greuter, J F Rahier, B Verstockt, C Abreu, A Albuquerque, M Allocca, M Esteve, F A Farraye, H Gordon, K Karmiris, U Kopylov, J Kirchgesner, E MacMahon, F Magro, C Maaser, L de Ridder, C Taxonera, M Toruner, L Tremblay, M Scharl, N
Journal of Crohn's and Colitis.2021; 15(6): 879. CrossRef
Management of hepatitis B virus infection in patients with inflammatory bowel disease under immunosuppressive treatment
Georgios Axiaris, Evanthia Zampeli, Spyridon Michopoulos, Giorgos Bamias
World Journal of Gastroenterology.2021; 27(25): 3762. CrossRef
Challenges in the diagnosis and management of inflammatory bowel disease in resource-limited settings in Asia
Rupa Banerjee, Partha Pal, Joyce Wing Yan Mak, Siew C Ng
The Lancet Gastroenterology & Hepatology.2020; 5(12): 1076. CrossRef
Nonimmunity against hepatitis B virus infection in patients newly diagnosed with inflammatory bowel disease
Seong Jae Yeo, Hyun Seok Lee, Byung Ik Jang, Eun Soo Kim, Seong Woo Jeon, Sung Kook Kim, Kyeong Ok Kim, Yoo Jin Lee, Hyun Jik Lee, Kyung Sik Park, Yun Jin Jung, Eun Young Kim, Chang Heon Yang
Intestinal Research.2018; 16(3): 400. CrossRef
Inflammatory bowel disease is no longer a risk factor of viral hepatitis infection in Asia
Eun Soo Kim
Intestinal Research.2017; 15(1): 5. CrossRef

6,260 View
53 Download
16 Web of Science
17 Crossref

Role of random biopsies in surveillance of dysplasia in ulcerative colitis patients with high risk of colorectal cancer: Sawan Bopanna, Maitreyee Roy, Prasenjit Das, S Dattagupta, V Sreenivas, V Pratap Mouli, Saurabh Kedia, Rajan Dhingra, Rajesh Pradhan, N Suraj Kumar, Dawesh P Yadav, Govind Makharia, Vineet Ahuja; Intest Res 2016;14(3):264-269. Published online June 27, 2016; DOI: https://doi.org/10.5217/ir.2016.14.3.264

Abstract PDF PubReader ePub

Background/Aims

Recent data suggest that the incidence of ulcerative colitis (UC) related colorectal cancer (CRC) in India is similar to that of West. The optimum method for surveillance is still a debate. Surveillance with random biopsies has been the standard of care, but is a tedious process. We therefore undertook this study to assess the yield of random biopsy in dysplasia surveillance.

Methods

Between March 2014 and July 2015, patients of UC attending the Inflammatory Bowel Disease clinic at the All India Institute of Medical Sciences with high risk factors for CRC like duration of disease >15 years and pancolitis, family history of CRC, primary sclerosing cholangitis underwent surveillance colonoscopy for dysplasia. Four quadrant random biopsies at 10 cm intervals were taken (33 biopsies). Two pathologists examined specimens for dysplasia, and the yield of dysplasia was calculated.

Results

Twenty-eight patients were included. Twenty-six of these had pancolitis with a duration of disease greater than 15 years, and two patients had associated primary sclerosing cholangis. No patient had a family history of CRC. The mean age at onset of disease was 28.89±8.73 years and the duration of disease was 19.00±8.78 years. Eighteen patients (64.28%) were males. A total of 924 biopsies were taken. None of the biopsies revealed any evidence of dysplasia, and 7/924 (0.7%) were indefinite for dysplasia.

Conclusions

Random biopsy for surveillance in longstanding extensive colitis has a low yield for dysplasia and does not suffice for screening. Newer techniques such as chromoendoscopy-guided biopsies need greater adoption.

Citations

Citations to this article as recorded by

Interlukin-23 inhibitors as an induction and maintenance therapy for moderate to severe ulcerative colitis: a systematic review and meta‑analysis of randomized controlled trials
Omar Saab, Hasan Al-Obaidi, Marwah Algodi, Asma Algodi, Yasir Rashid, Alhareth Al-Sagban, Hayder Alamily, Nooraldin Merza, Layth Alzubaidy, Andrew DuPont
Inflammation Research.2025;[Epub] CrossRef
Etrolizumab as an induction and maintenance therapy for ulcerative colitis: A systematic review and meta‐analysis of randomized controlled trials
Othman Saleh, Mohamed T. Abuelazm, Islam Mohamed, Alaa Ramadan, Mohammad Assaf, Ahmad Alzoubi, Majd M. AlBarakat, Basel Abdelazeem
JGH Open.2024;[Epub] CrossRef
Low prevalence of primary sclerosing cholangitis in patients with inflammatory bowel disease in India
Arshdeep Singh, Vandana Midha, Vikram Narang, Saurabh Kedia, Ramit Mahajan, Pavan Dhoble, Bhavjeet Kaur Kahlon, Ashvin Singh Dhaliwal, Ashish Tripathi, Shivam Kalra, Narender Pal Jain, Namita Bansal, Rupa Banerjee, Devendra Desai, Usha Dutta, Vineet Ahuja
Intestinal Research.2023; 21(4): 452. CrossRef
Colorectal Cancer Surveillance in Patients with Inflammatory Bowel Diseases: Chromoendoscopy or Non-Chromoendoscopy, That Is the Question
Roberto Gabbiadini, Ferdinando D’Amico, Alessandro De Marco, Maria Terrin, Alessandra Zilli, Federica Furfaro, Mariangela Allocca, Gionata Fiorino, Silvio Danese
Journal of Clinical Medicine.2022; 11(3): 509. CrossRef
Endoscopic Surveillance in Inflammatory Bowel Diseases: Selecting a Suitable Technology
Arianna Dal Buono, Roberto Gabbiadini, Federica Furfaro, Marjorie Argollo, Thaís Viana Tavares Trigo, Alessandro Repici, Giulia Roda
Frontiers in Medicine.2022;[Epub] CrossRef
Heterogeneity of Colorectal Cancer Progression: Molecular Gas and Brakes
Federica Gaiani, Federica Marchesi, Francesca Negri, Luana Greco, Alberto Malesci, Gian Luigi de’Angelis, Luigi Laghi
International Journal of Molecular Sciences.2021; 22(10): 5246. CrossRef
Histopathological study of endoscopic biopsies of large intestine
Manjiri N Karandikar, Purva Kulkarni, Smita Mulay, R C Nimbergi, N S Mani
Indian Journal of Pathology and Oncology.2021; 8(3): 340. CrossRef
Is histological remission of ulcerative colitis achievable?
Oleg V. Knyazev, Anna V. Kagramanova, Sergei G. Khomeriki, Asfold I. Parfenov
Terapevticheskii arkhiv.2021; 93(8): 975. CrossRef
A Systematic Review and Meta-Analysis on the Association between Inflammatory Bowel Disease Family History and Colorectal Cancer
Hadis Najafimehr, Hamid Asadzadeh Aghdaei, Mohamad Amin Pourhoseingholi, Hamid Mohaghegh Shalmani, Amir Vahedian-Azimi, Matthew Kroh, Mohammad Reza Zali, Amirhossein Sahebkar, Muhammad Naeem
Gastroenterology Research and Practice.2021; 2021: 1. CrossRef
Safety and effectiveness of adalimumab in the treatment of ulcerative colitis: results from a large-scale, prospective, multicenter, observational study
Haruhiko Ogata, Takashi Hagiwara, Takeshi Kawaberi, Mariko Kobayashi, Toshifumi Hibi
Intestinal Research.2021; 19(4): 419. CrossRef
Histological remission of ulcerative colitis with combined anti-cytokine and cell therapy
Oleg V. Knyazev, Sergey G. Khomeriki, Аnna V. Kagramanova, Albina A. Lishchinskaya, Olga A. Smirnova, Karina K. Noskova, Asfold I. Parfenov
Terapevticheskii arkhiv.2021; 93(12): 1435. CrossRef
Discovery and Validation of Methylation Biomarkers for Ulcerative Colitis Associated Neoplasia
Andrew D Beggs, Jonathan James, Germaine Caldwell, Toby Prout, Mark P Dilworth, Phillipe Taniere, Tariq Iqbal, Dion G Morton, Glenn Matthews
Inflammatory Bowel Diseases.2018; 24(7): 1503. CrossRef
Can histologic remission be a better prognostic factor and therapeutic target beyond endoscopic mucosal healing in patients with ulcerative colitis?
Hyo Jun Ahn, Sang-Bum Kang
Intestinal Research.2018; 16(1): 1. CrossRef
The Rising Incidence of Younger Patients With Colorectal Cancer: Questions About Screening, Biology, and Treatment
Louise C. Connell, José Mauricio Mota, Maria Ignez Braghiroli, Paulo M. Hoff
Current Treatment Options in Oncology.2017;[Epub] CrossRef
Screening strategy for colorectal cancer according to risk
Dong Soo Han
Journal of the Korean Medical Association.2017; 60(11): 893. CrossRef

6,461 View
59 Download
15 Web of Science
15 Crossref

First
Prev
Page of 1
Next
Last

Search